When to Order Imaging for Malignant or Aggressive Primary Musculoskeletal Tumor-Staging And Surveillance: ACR Appropriateness Decoded

When to Order Imaging for Malignant or Aggressive Primary Musculoskeletal Tumor-Staging And Surveillance: ACR Appropriateness Decoded

A patient is newly diagnosed with an aggressive primary bone or soft tissue tumor, such as an osteosarcoma or Ewing sarcoma. The initial workup is complete, and now the critical questions of staging and future surveillance arise. Does this patient need a PET/CT, a whole-body MRI, or a simple chest CT to evaluate for metastatic disease? For follow-up, what is the optimal modality to detect local recurrence versus distant spread? Ordering the correct imaging study is essential for accurate staging, treatment planning, and long-term management. This guide decodes the American College of Radiology (ACR) Appropriateness Criteria to help you select the most effective imaging for each clinical scenario.

What Does ACR Malignant or Aggressive Primary Musculoskeletal Tumor-Staging And Surveillance Cover?

This ACR guideline focuses specifically on the imaging required for patients with a known diagnosis of a malignant or aggressive primary musculoskeletal tumor. The recommendations are divided into two main clinical phases: initial staging and post-treatment surveillance. The criteria address the evaluation for common sites of metastasis, such as the lungs (pulmonary) and other sites (extrapulmonary), as well as the detection of local recurrence at the primary tumor site for both bone and soft tissue neoplasms.

These guidelines do not cover the initial diagnostic workup of an indeterminate musculoskeletal lesion. They are intended for use after a biopsy has confirmed a malignant or aggressive primary tumor. The recommendations also do not apply to metastatic disease to the musculoskeletal system from a non-musculoskeletal primary (e.g., lung cancer with bone metastases) or to the evaluation of benign primary bone tumors. The focus remains strictly on staging and surveillance for primary sarcomas and other aggressive musculoskeletal cancers.

What Imaging Should I Order for Malignant or Aggressive Primary Musculoskeletal Tumor-Staging And Surveillance? Recommendations by Clinical Scenario

The ACR provides specific recommendations based on the clinical question at hand, whether it is initial staging or long-term surveillance for recurrence. The choice of modality depends on the most likely sites of disease spread and the need to differentiate post-treatment changes from tumor recurrence.

For a patient undergoing initial staging, the primary goals are to define the extent of the local tumor (typically already done with MRI) and to detect distant metastases. To evaluate for pulmonary metastasis, the ACR rates CT chest without IV contrast as Usually appropriate. This modality provides high-resolution detail of the lung parenchyma, making it the most sensitive and specific test for identifying pulmonary nodules. In contrast, a standard chest radiograph is considered Usually not appropriate due to its lower sensitivity.

For the initial staging evaluation for extrapulmonary metastasis, FDG-PET/CT whole body is rated as Usually appropriate. This functional imaging study is highly effective for detecting metabolically active disease in bone and soft tissues throughout the body. While a whole-body bone scan May be appropriate, FDG-PET/CT is generally preferred for its ability to detect both osseous and soft tissue metastases simultaneously.

During post-treatment surveillance, the imaging strategy shifts. For monitoring asymptomatic patients with no suspected or known recurrence, surveillance for pulmonary metastasis is again best performed with CT chest without IV contrast, which is rated Usually appropriate. The frequency of this surveillance depends on the specific tumor type and institutional protocols.

For surveillance for local recurrence of a primary bone tumor, both radiography of the area of interest and MRI of the area of interest without and with IV contrast are rated Usually appropriate. Radiographs are excellent for assessing osseous structures and hardware, while contrast-enhanced MRI is superior for evaluating the surrounding soft tissues and detecting recurrent tumor enhancement. For surveillance of local recurrence in a primary soft tissue tumor, MRI of the area of interest without and with IV contrast is the primary modality and is rated Usually appropriate, as it provides the best soft tissue contrast to distinguish scar tissue from recurrent neoplasm.

ACR Imaging Recommendations Table

Adult vs. Pediatric Malignant or Aggressive Primary Musculoskeletal Tumor-Staging And Surveillance Imaging: Radiation Dose Tradeoffs

Many primary musculoskeletal malignancies, such as osteosarcoma and Ewing sarcoma, are most common in children and young adults. This demographic reality places a strong emphasis on minimizing radiation exposure according to the ALARA (As Low As Reasonably Achievable) principle. While the recommended imaging modalities are often the same for both adult and pediatric patients, the justification for using ionizing radiation and the protocols themselves must be carefully considered.

For instance, a chest CT for pulmonary metastasis surveillance carries a pediatric radiation dose level of ☢ ☢ ☢ ☢ (3-10 mSv), which is a higher tier than the adult dose of ☢ ☢ ☢ (1-10 mSv), reflecting the increased radiosensitivity of developing tissues. Similarly, whole-body FDG-PET/CT involves significant radiation exposure. In pediatric cases, clinicians and radiologists must weigh the clear benefit of accurate staging and surveillance against the long-term risks of cumulative radiation dose. This may lead to considering alternative, non-radiation-based modalities like whole-body MRI, which is rated as May be appropriate (Disagreement) for extrapulmonary staging, or adjusting surveillance frequency to reduce lifetime exposure.

Imaging Protocol Details for Malignant or Aggressive Primary Musculoskeletal Tumor-Staging And Surveillance

Once you’ve decided on the right study, the specific imaging protocol is critical for diagnostic accuracy. Key parameters like slice thickness on CT, MRI sequence selection, and the timing of contrast administration can significantly impact the ability to detect subtle disease. Our protocol guides provide detailed, practical information on technique and interpretation for the studies recommended in these guidelines.

• CT Chest Without Contrast
• CT Brain Without Contrast

Tools to Help You Order the Right Study

Navigating imaging guidelines and protocols can be complex. To streamline this process, GigHz offers several resources designed for ordering clinicians and radiologists to ensure appropriate and effective imaging is performed.

For clinical scenarios beyond malignant musculoskeletal tumors, the ACR Appropriateness Criteria Lookup tool provides a searchable interface to find the official ACR recommendations for hundreds of clinical presentations. This helps ensure your imaging orders are evidence-based and align with national standards.

To access detailed technical specifications for performing any of the imaging studies discussed, the Imaging Protocol Library offers a comprehensive collection of protocols. This resource is invaluable for ensuring consistency and quality, whether you are a radiologist setting up a sequence or a clinician wanting to understand the details of a test you are ordering.

When discussing the risks and benefits of imaging with patients, especially in pediatric cases, the Radiation Dose Calculator is a useful tool. It helps estimate and track cumulative radiation exposure from various imaging studies, facilitating informed conversations about dose management and the ALARA principle.

Why is CT chest without contrast preferred over with contrast for pulmonary metastasis evaluation?

For detecting pulmonary nodules, IV contrast does not typically improve sensitivity or specificity. The inherent high contrast between air-filled lung parenchyma and solid nodules makes non-contrast CT highly effective. Omitting contrast avoids potential risks such as contrast-induced nephropathy and allergic reactions, while also reducing cost and scan time, which is particularly beneficial for routine surveillance.

When is FDG-PET/CT more useful than a whole-body bone scan for staging?

FDG-PET/CT is generally more useful than a bone scan for staging most sarcomas because it can detect both osseous (bone) and soft tissue metastases. A bone scan only detects osseous metastatic disease with osteoblastic activity. Many sarcomas, like Ewing sarcoma and osteosarcoma, are FDG-avid, making PET/CT a more comprehensive single study for whole-body staging.

Why is MRI the primary modality for evaluating local recurrence?

MRI offers superior soft tissue contrast compared to CT or radiography. This is critical in the post-treatment setting, where it is necessary to distinguish between non-enhancing scar tissue, post-surgical fluid collections, and enhancing recurrent tumor. The use of IV gadolinium-based contrast agents further improves the conspicuity of recurrent neoplastic tissue.

Is a chest radiograph ever sufficient for pulmonary surveillance?

According to the ACR criteria, a chest radiograph is rated Usually not appropriate for both initial staging and surveillance of pulmonary metastases from aggressive musculoskeletal tumors. Its sensitivity for small nodules is significantly lower than that of CT. While it may be used in specific low-risk situations or when CT is contraindicated, it is not the standard of care for this clinical indication.

What does “May be appropriate (Disagreement)” mean for whole-body MRI?

This rating indicates that while the expert panel acknowledges the potential utility of the modality, there was not a consensus on its appropriateness. For whole-body MRI in extrapulmonary staging, some experts may favor it as a non-radiation alternative to PET/CT, especially in pediatric patients. However, others may have concerns about its sensitivity, specificity, or availability compared to the established standard of FDG-PET/CT, leading to a split recommendation.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026